An evolving virus demands innovative diagnostic technologies.
The entry of non-traditional funders – and the availability of non-traditional exits – has altered medtech, though probably only temporarily.
Mid-stage data with lenacapavir in treatment-naive patients justify pushing on; as for combos, Gilead is keeping its options open.
Promises to act on pharma’s financial toxicity increasingly seem to lack bite, but EQRX promises to follow its words with real action.
Awaiting crucial pivotal data, company reckons its plant-generated Covid-19 vaccine can still make a contribution to the pandemic.
The pivotal trial of Medtronic’s hypertension device came out more than a year ago, yet the company has still not sought approval.
The German tech investor Kizoo Ventures is committing €300m of its own cash to biotech start-ups working on rejuvenation and healthy lifespan expansion.
The success of previous forays into the clinical co-development space has enabled the UK venture firm to raise its biggest fund yet.
The new group reckons it has the most selective Tyk2 inhibitor yet. Patenting it is another issue.